chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial and follow up information has been received from a physician and a health professional concerning a 34 year old male patient who on 7/29/99 was vaccinated with a first dose of MMR. A second vaccination with MMR was administered on 2/22/00. On 2/17/05, it was reported that the patient is now going to medical school and titer for mumps is negative. The patient's IgG test for mumps titer was 0.91. The physician reported that he will  plant to revaccinated patient. Follow up information provided by the doctor office indicated that the medical school students left for Guam for the next three years to attend school. No further information is available. There was no product quality complaint involved. Additional information is not expected.
Severe pain in shoulder, causing nausea, started around 1:30 am and is still persisting.
This case was reported by a consumer and described the occurrence of nonspecific reaction in a 75-year-old female subject who was vaccinated with Influenza vaccine (manufacturer unspecified), Herpes zoster vaccine. A physician or other health care professional has not verified this report. The subject's concurrent medical conditions included breast cancer, allergy and dermatomyositis. On an unspecified date in 2010 the subject received a dose of Influenza vaccine (unknown) and later on an unspecified date the subject received unspecified dose of Herpes zoster vaccine (unknown). In 2010, at an unspecified time after vaccination with Influenza vaccine, the subject experienced "a reaction to the flu vaccine last year" [nonspecific reaction]. Her physician wanted her to received the Shingles vaccination later; on an unspecified time after vaccination with Herpes zoster vaccine, the subject experienced "had an increased reaction the second time. It was 4.5 inches by 4.5 inches" [nonspecific reaction]. She was advised by her physician advised to discontinuing receiving all vaccines. At the time of reporting the outcome of the nonspecific reaction was unknown.
swollen arm to elbow and hot to the touch. more inflammation and swelling located below injection site.
Vaccine was given to a patient after 31 days; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine was given to a patient after 31 days) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine was given to a patient after 31 days). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine was given to a patient after 31 days) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported by reporter. No treatment medication was reported by reporter.   Reporter did not allow further contact
Get really, really sick from them; Muscle aches; High fever; My immune system is down; I get like flu like symptoms really bad from these vaccine; Couldn't get out of bed I was too weak; Couldn't get out of bed I was too weak, my husband had to help me; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 67-year-old female patient received BNT162b2 (BNT162B2), in Feb2021 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Factor V" (unspecified if ongoing), notes: Caller states she has Factor V and COPD "really bad" and takes blood thinners.; "COPD" (unspecified if ongoing), notes: Caller states she has Factor V and COPD "really bad" and takes blood thinners. The patient took concomitant medications. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "Get really, really sick from them"; MYALGIA (non-serious), outcome "unknown", described as "Muscle aches"; PYREXIA (non-serious), outcome "unknown", described as "High fever"; IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "My immune system is down"; INFLUENZA LIKE ILLNESS (non-serious), outcome "unknown", described as "I get like flu like symptoms really bad from these vaccine"; ASTHENIA (non-serious), outcome "unknown", described as "Couldn't get out of bed I was too weak"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious), outcome "unknown", described as "Couldn't get out of bed I was too weak, my husband had to help me".  Additional information: The patient stated she has had two vaccines of Pfizer COVID and the booster. The Pfizer COVID booster was last Oct2021. She was getting ready to have the updated one. She stated she really gets sick from them and enquired whether she should still be able to get them if she got muscle aches and fever or immune system was down. She stated that she didn't take anything for the fever before and asked if she can take anything or Tylenol for the fever if she gets a fever. This will be her 4th time getting the Pfizer COVID vaccines, her symptoms only last 24 hours, she guess it's not that bad, the fever and muscle aches start at nighttime after getting the injections. When she had it, she was unable to get out of bed she was too weak, her husband had to help her. She stated that her husband reported her symptoms back in Oct2021, when she received her booster on 28Oct2021; and he would have reported in Mar2021 and in Feb2021 when she had her 1st and 2nd dose. She had side effects from first 2 vaccines and the first booster; immune system down real bad and got really bad side effects from that. Consumer further stated, she got like flu like symptoms really bad from these vaccine and high fever.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201233152 same patient/drug/AE, different dose;US-PFIZER INC-202201232892 same patient/drug/AE, different dose;
Noticed the shoulder that the vaccine had a large reddened skin eleven days after the vaccine.  Skin feels slightly warm.  About 4 inches long and 1 and half inches wide.
2 hours after vaccination patient experienced palpitations, and lightheadedness for 45 minutes,  A bruise 1 inch long and 1/2 inch wide appeared, a red spot 1 inch wide and 1 and 1/2 inches long appeared. Patient took xanax and symptoms disappeared.
I am 14 weeks pregnant, estimated due date of 3/28/2022. after second moderna vaccination, i have been experiencing twicthing in my tongue, fever, headaches, and abdominal cramping
38mm welt, itching, warm feeling, some mild pain when lifting anything, painful to touch.
feeling a little queasy; This is a spontaneous report from a contactable consumer(patient's husband). A female patient of unspecified age received BNT162B2(lot number and expiration date not provided) via an unspecified route of administration on unspecified date at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The reporter reported wife was feeling a little queasy after receiving a vaccine dose. The outcome of the event was unknown.  Information on the lot/batch number has been requested
Fever (99.2F), chills, body aches, and fatigue the day of vaccination. Persistent left shoulder (site of vaccination administration) soreness and fatigue 10 days post-vaccination.
Woke up to rapid heartbeat and funny feeling in tips of fingers and with headache the day after receiving booster shot.
I started having a sore throat, headache and body chills. Eventually, that added with coughing, fatigue, and muscle aches. I decided to get tested on 07/24/2022 by taking an at-home COVID-19 test which came back positive. I called my doctor who prescribed me PAXLOVID to help subside my symptoms. Since taking the prescription, the fatigue, headache, body chills and muscle aches have gone away, but I'm still having a sore throat and light cough every now and then.
constant crying x 24 hrs; no redness @ site of inject; whole leg was sore, t103.1 only dec w/Advil; ear soreness p/elevated temp -t101.0;
Pain; Discomfort; I haven't been feeling well; Dizzy/I was so dizzy that my eyes were turning all over; Headaches; Weakness; Feeling very bad; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 78 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 18Mar2021 (Batch/Lot number: unknown) at the age of 78 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious) with onset 19Mar2021, outcome "not recovered", described as "Dizzy/I was so dizzy that my eyes were turning all over"; HEADACHE (non-serious) with onset 19Mar2021, outcome "not recovered", described as "Headaches"; ASTHENIA (non-serious) with onset 19Mar2021, outcome "not recovered", described as "Weakness"; FEELING ABNORMAL (non-serious) with onset 19Mar2021, outcome "not recovered", described as "Feeling very bad"; PAIN (non-serious), outcome "unknown", described as "Pain"; DISCOMFORT (non-serious), outcome "unknown", described as "Discomfort"; MALAISE (non-serious), outcome "unknown", described as "I haven't been feeling well". Therapeutic measures were taken as a result of dizziness, headache, asthenia, feeling abnormal, pain, discomfort, malaise.  Additional information: The patient had no additional vaccines administered on same date of BNT162B2. The patient had not received any other vaccines within 4 weeks prior vaccination. The events did not result to ER visit. The patient took TYLENOL as treatment of the events.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
extreme muscle pain in the arm/shoulder/neck area. this could have been contributed to recent increase in weight lifting. however then by 10/17/21, lymph nodes in arm pit were swelling. on morning of 10/18/21 the entire arm pit area, part of right breast and chest, down into the right side around the breast were quite swollen, sore. little warmth to touch of the arm area where injection was given.
approx 30 mins p/vax & arrive home mother reported nose stopped up, c/o throat tightening-exp some resp difficulty @ arrival to ER;
Aching in legs, weakness, numbness, shortness of breath, admitted to hospital 10/31/06.  11/21/06 Received medical records from hospital which reveal patient admitted 10/31/06 for progressive generalized weakness which began 10/29 associated with paresthesias & progressive gait disorder. Patient admitted for further w/u to exclude cord compression. There was no obvious muscle weakness on exam of 11/1 & it was felt that patient had quickly resolved GBS.  She was D/C at that time.  Patient was readmittted on 11/2/06 with dx of GBS & respiratory failure.  Noted to have phrenic nerve involvement requiring bipap support after being seen with SOB. Treated with plasma exchange x 5 & improved well.  D/C to home 11/7/06 PMH: asthma, obesity, HTN, osteoporosis, restless leg syndrome. Final DX: GBS w/respiratory failure, resolving./ss
Bad rash all over body. Symptoms included wheals, swelling of skin, and itching. Symptoms relieved with Caladryl Clear lotion (applied as needed) and oral Benadryl  (50mg/q 6hrs) . Symptoms subsided after 5 days.
Vaccine was not reconstituted. Only diluent was given orally.    NO ADVERSE EFFECTS. patient will need to be re-vaccinated due to error.
had shingles; This case was reported by a nurse via call center representative and described the occurrence of shingles in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number 227FL, expiry date 26th November 2021) for prophylaxis.   The patient's past medical history included shingles (had shingles prior receiving 1st dose). Previously administered products included Shingrix (1st dose was administered in October 2019).   In January 2020, the patient received the 2nd dose of Shingrix. In January 2020, 1 week after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The patient had shingles prior to the first dose and after receiving the 2nd dose, had shingles a week later. She provided 2 lot number and the 2nd one provided did not pull up a valid Shingrix dose in the batch finder. It was unclear which lot number goes with which administration date. The reporter consented to follow up.
While waiting after her booster shot Pt started feelin "funny" Her eyes felt like they were swelling and also her face. I was called in and she had no redness or edema around her eyes or face and she denied any SOB or feeling that her throat was swelling.  Her vitals were all WNL and her oxygen sat was 98% .Because of her long history of adverse reactions to medications the decision was made to give her 50mg of Benadryl orally. She tolerated this well and said 10 minutes later that her face and eyes felt better but then at the 15 minute mark she C/O chest discomfort and a funny feeling around her eyes. Her B/P was 178/72 but no SOB. The ambulance was called and she was taken to the ER locally. She was released a few hours later and her daughter said "everything turned out OK. I called the next day and she was feeling well except for a sore arm at the injection site.
shingles even though vaccinated with 2 doses/suspected Vaccination failure; shingles; This case was reported by a other health professional via sales rep and described the occurrence of vaccination failure in a elderly male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.     Additional Information: GSK Receipt Date: 16-MAY-2022 Reporter's comment: The patient came down with bad case of shingles even though vaccinated with the 2 doses of Shingrix received 2 years prior to the reporting date. The reporter agreed to follow up.  Additional supportive information: This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.
give her a shot in her knee for pain; This is a spontaneous report from a contactable consumer (patient) via medical information team and Pfizer sponsored program. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 09Mar2021 (Lot number was not reported) as dose 1, single for covid-19 immunisation. The patient medical history and patient's concomitant medications were not reported. On 13Mar2021 (also reported as 12Mar2021), patient went to the knee doctor and he gave her a shot of something in her knee for pain as treatment. Patient was not sure what he gave her but thinks it may have been steroids. She asked doctor if the shot would affect the efficacy of the vaccine and he told her no and now she was reading that it could. Her 2nd dose was on 25Mar2021, 16 days after 1st dose and wondering if she should postpone her second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Today is mild discomfort and fair to good mobility; Sciatica; The pain I experienced Sun through Tue limited my mobility significantly and I had trouble sitting and changing positions.; This is a spontaneous report from a non-contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 02Apr2021 at 10:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included no diagnosed illnesses and no chronic health conditions. The patient had no known allergies to medications, food, or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 07:00, the patient experienced sciatica. Sciatica was really bad on Sunday through Tuesday. The patient had never had sciatica and the pain he experienced Sunday through Tuesday limited the patient's mobility significantly and he had trouble sitting and changing positions. The patient did not know if it was coincidental but he had never had sciatica ever before. The pain was concentrated below his hip on the outside. He would occasionally have shooting pains with tingling down his leg. It was a bizarre experience. On 07Apr2021, the patient experienced mild discomfort and fair to good mobility and sciatica was much better. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sciatica was really bad on Sunday through Tuesday, limited the patient's mobility significantly and he had trouble sitting and changing positions and mild discomfort was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
pt fainted while attending school; seemed to be having difficulty staying awake, was burning up, seemed out of it, i.e., like was sick & uncomfortable, t101 ax, vagal nerve response;
pt seen for check-up on 11JUN96 4PM-had nl check-up x/diaper rash;pt recv vax & sent home in good condition;pt taken to babysitter appeared a little drowsy @ 8-9AM;thought to be sleeping when found dead;
pain; warm; rash; This case was reported by a pharmacist via call center representative and described the occurrence of pain in a 64-year-old male patient who received Herpes zoster (Shingrix) (batch number 9235B, expiry date 29th November 2021) for prophylaxis.   On 12th July 2019, the patient received Shingrix. On 14th July 2019, 2 days after receiving Shingrix, the patient experienced pain, feeling of warmth and rash. On an unknown date, the outcome of the pain, feeling of warmth and rash were not recovered/not resolved.   The reporter considered the pain, feeling of warmth and rash to be related to Shingrix.  Additional details were provided as follows: The patient received dose of Shingrix in the left deltoid. The reporter wanted to  speak to medical information on how to instruct patient to treat these symptoms. There was discrepancy between the outcome reported in the structured field (not recovered) and the outcome reported in the source document (recovering)
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  The reporter reported that because their facility had not been able to download the digital data logger, they had been put on hold by the State at the moment and cannot administer the Moderna COVID-19 vaccine to patients until an assessment by the state was made. There had been no power outages that would have impacted the Moderna vaccine. However, the reporter reiterated that because the facility was unable to download the digital data logger, this issue was treated as a temperature excursion. The reporter was unable to download the data logger for the months of December 2021, January 2022 and February 2022. The reporter was filling out a temperature excursion assessment with the State.  The reporter mentioned that the patient had been administered dose while the temperature excursion assessment was ongoing. The reporter also reported that, no adverse reactions were reported by the patient.  No treatment information was provided by the reporter.
No additional adverse effects reported; A patient was administered improperly stored VARIVAX; This spontaneous report has been received from a medical assistant concerning 17-month-old child of unknown gender.  Information regarding the patient's current conditions, medical history, concomitant therapies, drug allergies or reactions, and historical drugs were not provided.  On 18-JUN-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot number S028924 has been verified to be a valid lot number, expiration date reported and validated as 16-SEP-2021) as prophylaxis (concentration, dose, dose description, frequency of vaccination scheme and anatomical location of vaccination were not reported).   The varicella virus vaccine live (Oka/Merck) (VARIVAX) underwent a temperature excursion in the rage of 15 to 46 degrees Fahrenheit (29.5 degrees Fahrenheit) for 67 hours, as recorded by the data logger (product storage error). The vaccine was reconstituted with a properly stored sterile diluent.  There were no previous temperature excursions.No adverse effects were reported for the patient.  This is one of several reports received from the same reporter.; Sender's Comments:  US-00950713-2007USA003079:
Received ZOSTAVAX on a Thursday. When awoke on Sunday am had a stiff neck - hurting into shoulder and ear on (L) side. Continues to be stiff.
Localized hive-like rash along medial surface of right arm (site of injection) extending from mid-humerus to distal ulna. The rash evolved over 1 week. Superficial cellulitis ensued. Lesion began as blisters, 2 hours after Havrix injection.